Methods for the treatment and prevention of lung infections caused by gram-positive bacteria, fungus, or virus by administration of tafenoquine
Methods and composition for treating or preventing a lung infection, or related symptoms, caused by a bacterium, fungus, and/or virus using an effective amount of tafenoquine are disclosed. Methods and compositions for treating or preventing a lung infection in a human that is infected with SARS-CoV-2 using tafenoquine are disclosed.
1 . A method for treating a SARS-CoV-2 infection in a human subject, said method comprising administering to said human subject an effective amount of tafenoquine, a pharmaceutically-acceptable salt thereof, or a pharmaceutical composition comprising tafenoquine.
2 . The method according to claim 1 , further comprising administering a second agent.
3 . The method according to claim 1 , wherein the human subject is glucose-6-phosphate dehydrogenase (G6PD)-normal.
4 . The method according to claim 1 , wherein the human subject is symptomatic of the SARS-CoV-2 infection prior to initial administration.
5 . The method according to claim 1 , wherein said human subject is asymptomatic of the SARS-CoV-2 infection prior to initial administration.
6 . The method according to claim 1 , wherein said administration is via oral and/or intravenous and/or intra-arterial and/or sub-lingual and/or buccal route(s).
7 . The method according to claim 1 , wherein at least seven doses of about 100 mg-600 mg are administered.
8 . The method according to claim 1 , wherein about 100 mg to about 600 mg is administered in one or more initial dose(s).
9 . The method according to claim 1 , wherein about 100 mg to about 600 mg is administered in one or more initial dose(s) and in one or more subsequent dose(s).
10 . The method according to claim 1 , wherein three initial doses are administered once per day for three days, optionally comprising administration of one or more additional subsequent doses.
11 . The method according to claim 1 , wherein three or four initial doses are administered, optionally comprising administration of one or more additional subsequent doses.
12 . The method according to claim 9 , wherein the subsequence dose(s) is administered once per week.
13 . The method according to claim 9 , wherein the subsequence dose(s) is administered once per day.
14 . The method according to claim 8 , wherein the initial dose(s) is about 200 mg.
15 . The method according to claim 8 , wherein the initial dose(s) is about 150 mg.
16 . The method according to claim 8 , wherein the initial dose(s) is about 100 mg.
17 . The method according to claim 9 , wherein the subsequent dose(s) is about 200 mg.
18 . The method according to claim 9 , wherein the subsequent dose(s) is about 150 mg.
19 . The method according to claim 9 , wherein the subsequent dose(s) is about 100 mg.
20 . The method according to claim 9 , wherein the first subsequent dose is administered seven days after the last initial dose.
21 . The method according to claim 9 , wherein the initial dose is about 200 mg and is administered once a day for three days, and wherein the subsequent dose is about 200 mg and is administered once a week.
22 . The method according to claim 9 , wherein there is one subsequent dose administered approximately one week after the third initial dose.
23 . The method according to claim 8 , wherein there are no subsequent doses administered.